Company News
Ten‑Year Dedication to Building Standards, Setting Industry Benchmarks Together — Shenyang Cell Center 10th‑Anniversary Series Report
Shenyang Cell Center (or SYCC) was founded in June 2016 with support from local government and China Medical University.Over the past decade,it has grown into a core benchmark for the cell industry in Northeast China.
Focused on cell‑technology innovation, guided by clinical requirements and driven by regional development responsibilities,the company has stepped out of a solid road of high-quality development with support from governments, industry peers and partners.
To celebrate the 10th anniversary, we have specially planned this report to review the ten-year journey of Shenyang Cell Center.
2016: Benchmarking Global Practices, Charting the Future
In 2016,the "Wei Zexi Incident" sparked public concern over the cell therapy sector,clinical application of cell therapy technologies was subsequently suspended.However,Shenyang Cell Center set a clear direction: compliance is the bottom line, and standards are the lifeline.To sustain compliant and long‑term growth,the company adopted benchmarking international standards as its founding principle,defined its construction standards and development targets.
2017: Building Hardware Foundations, Prioritizing Quality
In 2017,Shenyang Cell Center received the first major industry recognition——its GMP laboratory has successfully passed the environmental testing conducted by a third-party organization. This accreditation verified that the laboratory’s hardware facilities and environmental control capabilities,laying a foundation for standardized cell‑product preparation and storage.The laboratory has successfully passed accreditation 18 times over the following nine years, demonstrating the ability of strict management.
The same year, company cooperated with Shengjing Hospital of China Medical University to carry out the R&D project” Umbilical Cord Blood Combined with Umbilical Cord Mesenchymal Stem Cell Transplantation for Pediatric Severe Aplastic Anemia”;it also partnered with Shenyang Jinghua Hospital on the R&D project “Autologous Endometrial Cell Therapy for Infertility” These early‑stage research collaborations with top regional medical institutions attest to the industry’s recognition of SYCC’s technical capacity.
2018: Aligning with Standards, Establishing Initial Management Systems
In 2018,SYCC took a crucial step in quality system construction—“preparation and storage of stem cells and immune cells” obtained ISO 9001:2015 Quality Management System certification.This certification marked the company’s transition from hardware met target to whole process of quality management.SYCC has passed eight consecutive recertifications , proving its stable technical workflows and strict quality management.
The same year,SYCC and Shengjing Hospital of China Medical University obtained funding of “Study on Comprehensive Therapy for Intrauterine Adhesions”,further deepening the capability of innovation.
2019: Gaining International Accreditation, Connecting with the World
2019 is the year that entered the internationalization process of SYCC.The company passed AABB (American Association of Blood Banks) accreditation successfully and became an AABB member, confirming that its quality management systems for cell preparation and storage was recognized by global industry authority.
The same year,SYCC assigned ISBT (International Society of Blood Transfusion) identification code 90068 and has passed seven consecutive reaccreditations.This code provided unique identify label for international traceability and standardization of cell products.The company achieved a critical leap from domestic standards to international accreditation in quality management field.
2020: National-Level Validation, Deepening Clinical Work
In 2020,SYCC successfully passed the external quality assessment administered by the National Health Commission of China and received authoritative national verification.Since then,the detection capability of company has passed third-party verification for six consecutive years,guaranteeing authoritative quality reports for all services.
In the same year, the company continued to strengthen its efforts in clinical research cooperation. Together with China Medical University, it was awarded a National Natural Science Foundation of China project, focusing on the mechanistic study of thermosensitive heparin-poloxamer-rhFGF9 hydrogel in facilitating hair follicle cycle transition and regeneration. It obtained a Liaoning Provincial Science and Technology Project in collaboration with Liaoning Provincial People’s Hospital to conduct clinical research on autologous DC-CTL cell therapy for pulmonary squamous cell carcinoma. Jointly with the Stomatological Hospital of China Medical University, it won a Key R&D Project of Liaoning Province to investigate the role of autologous adipocytes in regenerative repair of alveolar bone defects.In partnership with Liaoning Provincial People’s Hospital, it also secured a Shenyang Medical-Industrial Integration Science and Technology Project to advance the research on DC-CTL cell therapy for hepatocellular carcinoma.
From fundamental research to clinical translation,multiple high-level projects has been launched,manifesting SYCC’s reputation and influence as cell technology R&D platform.
2021: Industry Leadership, Dual International Accreditations
In 2021,SYCC reached a milestone in its industry recognition journey:the company passed AABB accreditation for both cell therapy and cell storage services,becoming the world’s 10th institution to achieve this distinction.This achievement propelled the company into leading echelon of global cell industry ,confirming that SYCC’s quality management systems for cell therapy products and cell storage services reach international top-tier standards.The Company has passed six consecutive AABB reassessments,enhancing capacity for international market expansion.
The same year,SYCC became the leader of the Liaoning provincial and Shenyang Municipal Industry-university-Research Alliance,evolving from a follower of technical standards into an organizer of the regional industrial ecosystem.In clinical research,SYCC launched numerous cooperative projects with medical institutions ,including Shengjing Hospital, the Affiliated Stomatological Hospital, the Fourth Affiliated Hospital of China Medical University, Shenyang Maternity and Child Health Hospital and Shenyang Jinghua Hospital. The research covers multiple clinical areas such as intrauterine adhesion repair, diabetic refractory skin defects, abdominal wall reconstruction for senile hernia, stretch mark repair, and endometrial regeneration. The collaboration network keeps expanding, and the technology outreach capacity has been markedly enhanced.
2022: Formulating Industry Standards, Prioritizing Regulation
In 2022, Shenyang Cell Center joined the China Stem Cell Industry Alliance as a council member.In addition, SYCC led a soft science project by the Liaoning Department of Science and Technology: Construction and Management Specifications for Liaoning Comprehensive Cell Banks and Cell Preparation Centers.Together with more than 20 hospitals and enterprises, it formulated three industrial standards and specifications: “Specifications for the Establishment and Management of Cell Preparation Institutions”, “Specifications for the Establishment and Management of Cell Banks”, and “Specifications for Cell Storage Services”.It filled in blanks of regional cell industry construction and promoted standardized development of cell preparation and storage services.
Meanwhile, SYCC has awarded a Shenyang Science and Technology Program medicalengineering integration project in partnership with the First Affiliated Hospital of China Medical University, and a key Shenyang “OpenBidding for Unmet Technical Challenges” project together with Shanghai Jiao Tong University Cancer Institute. It continued cuttingedge R&D on mesenchymal stem cell exosomes and islettissue engineering.
2023: Zero‑Defect Re‑accreditation, Advancing Scientific Research
In 2023, Shenyang Cell Center passed AABB reassessment with zero defect,which meant every link of cell products quality management all reached international standard,it earned high recognition from global industry authorities.The same year,AABB granted China’s first CSM (Cellular Starting Material) supplier qualification certificate to SYCC,making it the first domestic institution to receive this qualification.Since then,the company has held AABB CMS qualification for four consecutive years,possessing the capacities to supply qualified raw cellular materials to enterprises, research institutes and hospitals for domestic and overseas.
Also in 2023, SYCC and China Medical University were awarded a Liaoning Provincial Science and Technology Program“Investigation on the Therapeutic Effect and Mechanism of Hypoxia-Preconditioned Mesenchymal Stem Cells in Systemic Lupus Erythematosus”。
The company also expanded clinical research cooperation with Liaoning Maternity and Child Health Hospital, Dalian Women and Children’s Medical Group and other partners,enriching application scenes for cell technology.
2024: Consolidating Foundations, Preparing for Future Growth
In 2024, Shenyang Cell Center successfully completed third ISO 9001 recertification, gaining renewed authoritative validation of the sustainability and stability of its quality management system.
During 2024, six Class III medical device products completed preregistration R&D, marking a major milestone for SYCC’s product pipeline toward highend medical devices.During the year, the company was granted two invention patents, namely “Preparation Method of Decellularized Human Amniotic Membrane” and “A Method for Culturing Natural Killer Cells”, together with a number of utility model patents including “A Device for Cell Rehydration and Recovery”, “A Rapid Cell Counting Device”, and “A Novel Cell Factory”.Intellectualpropertyright layout kept expanding.
2025: Continuous Improvement, Industry-Wide Evaluation
In 2025, Shenyang Cell Center once again passed its AABB reassessment with outstanding outcomes , retaining its dual international accreditations year after year.For clinical collaboration, SYCC established new cooperations with institutions including Gemflower Medical Jilin Chemical‑Hospital and the First Affiliated Hospital of Harbin Medical University,advancing clinical exploration of cell technology for intrauterine adhesion prevention and ischemic heart failure treatment.Its cooperation area expanded beyond Liaoning Province to Northeast China, growing its portfolio scientific research programs.
2026: Embracing New Regulatory Rules, Achieving Win-Win Hospital-Enterprise Collaboration
With the official implementation of State Council Decree No. 818 on May 1st 2026,ushering in a new era of regulated growth for the cell therapy industry.Relying ten years of solid technological accumulation and a wealth of hospital enterprise R&D achievements,SYCC embraces new development opportunities by the new regulations.Multiple stem cell and immune cell therapy technologies and clinical research projects have passed clinical evaluation at several tertiary hospitals and advanced into project filing procedures.
From its GMP laboratory national assessment success in 2017 to receiving China’s first AABB Cellular Starting Material supplier qualification; from ISO 9001 quality management system certification to becoming the world’s 10th (and China’s 4th) institution with AABB dual accreditation; from single item clinical research cooperation to leading regional industry standard formulation——Shenyang Cell Center’s strict quality、standard and good faith cooperation,establishing a professional, compliant and reputable brand within the cell therapy sector.
Ten years of striving research proves that quality earns trust;ten years of perseverance earns recognition across the industry.Standing at the new starting point of its 10th anniversary,following the guidelines of international standards and national industry specifications,SYCC will keep enhancing core competitiveness for its cell technology products and services, deepen collaboration with medical institutions and research organizations, and write new chapters of industry excellence, contributing to high‑quality development of China’s cell‑therapy industry.
Shenyang Cell Center — looking forward to the next ten years.